€8.00
-0.01 (-0.12%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GBT.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
35 interventional · 7 observational · 32 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsNCT04373564Change of motor function from baseline to year 5 in comparison to a matched non-GBCA-exposed control groupNon-randomized · Open-label · Other | Phase 4 | Recruiting | Procedure: Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements · Drug: Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol | Motor Function, Cognitive Function, Contrast Media | 2,076 | 2028-12-31 | in 864 d | 2026-01-22 |
| Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseaseNCT07348640Non-inferiorityRandomized · Quadruple-masked · Diagnostic | Phase 3 | Recruiting | Drug: gadopiclenol, Gadoterate meglumine (Dotarem) | Steno-occlusive Disease | 315 | 2027-12-31 | in 498 d | 2026-08-13 |
| Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and ChildrenNCT06010173results2026-06-25Lesion Visualization on Paired Images: Border DelineationRandomized · Quadruple-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Gadopiclenol, Comparator (gadobutrol) | Lesion in Body Region, CNS Lesion | 240 | 2025-05-06actual | — | 2026-06-25 |
| Performance of Elucirem in DSC-MRI Perfusion of Brain GliomasNCT06057168results2026-01-29Diagnostic Quality of Cerebral Blood Volume (CBV) Map of Dynamic Susceptibility Contrast MRI (DSC-MRI) PerfusionRandomized · Single-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Elucirem, Dotarem | Brain Tumor, Primary, Brain Tumor, Recurrent | 138 | 2024-11-28actual | — | 2026-01-29 |
| Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of AgeNCT05590884results2025-10-28Area Under the Curve (AUCinf)Non-randomized · Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Gadopiclenol | Central Nervous System Diseases, Pediatric Disorder, Body Indication | 36 | 2024-09-30actual | — | 2025-10-28 |
| Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-upNCT05316077observationalRate of leakage/breakage | — | Unknown status | — | Oncology | 50 | 2023-03-31 | — | 2022-09-15 |
| Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT ExaminationNCT05537779observationalSafety of Optivantage | — | Unknown status | Device: CT examination | Patient Participation | 100 | Dec 2022 | — | 2022-09-13 |
| Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy VolunteersNCT04906005CmaxRandomized · Triple-masked · Other | Phase 1 | Completed | Drug: gadopiclenol, Placebo | Pharmacokinetics | 27 | 2021-07-27actual | — | 2021-10-07 |
| A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization ProceduresNCT02625389results2025-10-10Adverse Drug Reactions During the Embolization ProcedureOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Lipiodol Ultra Fluid with surgical glues | Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma, Arteriovenous Malformations | 132 | 2021-05-12actual | — | 2025-10-10 |
| Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)NCT03986138results2025-10-27Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRIRandomized · Quadruple-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution | Lesion in Body Region | 324 | 2020-12-09actual | — | 2025-10-27 |
| Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)NCT03996447results2025-09-22Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRIRandomized · Quadruple-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial | CNS Lesion, Blood Brain Barrier Defect | 260 | 2020-09-11actual | — | 2025-09-22 |
| Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRINCT03749252results2022-06-01Elimination Half-lifeNon-randomized · Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: P03277 | Central Nervous System Indication, Pediatric Patients, Body Indication | 80 | 2019-12-18actual | — | 2022-06-01 |
| Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC DiagnosisNCT02973516results2021-10-06Diagnostic Value Evaluation for HCCOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: P03277 at 0.1 mmol/kg, P03277 at 0.05 mmol/kg | Chronic Liver Disease, HepatoCellular Carcinoma | 41 | 2019-04-04actual | — | 2021-10-26 |
| Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal FunctionNCT03657784AUCNon-randomized · Open-label · Diagnostic | Phase 1 | Completed | Drug: P03277 | Renal Insufficiency, Healthy Volunteers | 40 | 2019-02-01actual | — | 2019-10-22 |
| Cardiac Safety Evaluation of P03277NCT03657264results2019-08-22Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)Randomized · Triple-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: P03277 0.1 mmol/kg, Moxifloxacin 400mg, NaCl 0.9%, P03277 0.3 mmol/kg | Healthy Volunteers | 48 | 2018-06-07actual | — | 2022-07-18 |
| P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)NCT02633501results2019-05-08Contrast to Noise Ratio (CNR) DifferenceRandomized · Quadruple-masked · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: P03277, Gadobenate dimeglumine · Device: MRI | CNS Lesion, Blood Brain Barrier Defect | 312 | Jan 2018actual | — | 2021-10-25 |
| Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem AdministrationNCT01467271results2019-02-04observationalNumber of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of DotaremStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | — | Renal Insufficiency | 540 | Jun 2017actual | — | 2019-02-04 |
| DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 YearsNCT02411201results2017-03-09Area Under the Curve of DOTAREM in PlasmaOpen-label · Diagnostic | Phase 4 | Completed | Drug: DOTAREM | Magnetic Resonance Imaging | 51 | Oct 2015actual | — | 2017-03-09 |
| DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCCNCT01806740results2019-08-08Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to SorafenibOpen-label · Diagnostic | Phase 4 | Terminatedsponsor's stated reason: The planned number of enrolled patients was not reached. | Drug: Gadoterate meglumine | Hepatocellular Carcinoma | 37 | 2015-10-12actual | — | 2019-08-08 |
| Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain TumorsNCT02034708results2016-10-25Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or ExcellentRandomized · Quadruple-masked · Diagnostic | Phase 4 | Completed | Drug: Dotarem®, Gadovist®/Gadavist® | Primary Brain Tumor | 279 | Sep 2015actual | — | 2016-12-30 |
| Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain LesionsNCT03603106results2019-07-12Pharmacokinetic (PK) Parameter CmaxRandomized · Triple-masked · Diagnostic | Phase 1/2 | Completed | Drug: P03277, Placebo | Healthy Volunteers, Brain Lesion | 142 | 2015-04-17actual | — | 2021-05-14 |
| Hepatic Xenetix-CT PerfusionNCT01639703results2017-07-13Blood Volume (BV) According to Degree of Lesions DifferentiationOpen-label · Diagnostic | Phase 4 | Completed | Drug: Xenetix-CT perfusion imaging | Hepatocellular Carcinoma | 96 | Oct 2014actual | — | 2017-07-13 |
| Post-marketing Surveillance Study for Evaluation of Dotarem SafetyNCT03048006results2017-05-02observationalFrequency of Adverse Events | — | Completed | Procedure: MRI with Dotarem | Contrast-enhanced MRI With Dotarem | 44,456 | Dec 2013actual | — | 2017-05-02 |
| Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance MammographyNCT03041298results2017-05-02observationalImage Quality | — | Completed | Procedure: MR mammography with Dotarem | MR Mammography With Dotarem | 1,537 | Oct 2013actual | — | 2017-05-02 |
| Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)NCT01523873results2016-01-22observationalFrequency of Adverse Events | — | Completed | — | General Safety Profile of DOTAREM | 35,921 | Jul 2013actual | — | 2017-02-24 |
| Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT AngiographyNCT01255722results2015-12-16Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading AssessmentRandomized · Double-masked · Diagnostic | Phase 4 | Completed | Drug: iobitridol, iopromide, iomeprol | Coronary Artery Disease | 468 | Sep 2012actual | — | 2015-12-16 |
| Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK InjectionNCT00811863observationalThe primary outcome measure will be the diagnosis of NSF based on clinical assessments and patient telephone calls through 24 months of follow-up. | — | Withdrawnsponsor's stated reason: Study drug currently unavailable | — | Nephrogenic Systemic Fibrosis, Renal Insufficiency | 0 | 2012-05-17actual | — | 2017-08-02 |
| Safety and Dialysability of Dotarem® in Dialysed PatientsNCT01449266results2015-06-08Dialysability of Dotarem® in Dialysed PatientsOpen-label | Phase 1 | Completed | Drug: Dotarem® IV injection at 0.1 mmol/kg | End-stage Renal Failure | 10 | Mar 2012actual | — | 2015-07-08 |
| Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) LesionsNCT01211873results2014-05-29MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" EvaluationRandomized · Quadruple-masked · Diagnostic | Phase 3 | Completed | Drug: Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine) | Diagnostic Self Evaluation, Central Nervous System Diseases | 416 | Nov 2011actual | — | 2019-04-18 |
| Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary AtherosclerosisNCT01254552results2019-05-31Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes MellitusOpen-label · Diagnostic | Phase 4 | Completed | Drug: iobitridol, gadoterate meglumine | Type 2 Diabetes Mellitus, Coronary Atherosclerosis | 351 | Sep 2011actual | — | 2019-05-31 |
| Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial DiseaseNCT01026389results2012-12-11Intra-patient Accuracy (Percent Agreement), On-site DataRandomized · Quadruple-masked · Diagnostic | Phase 4 | Completed | Drug: Dotarem, Gadovist | Peripheral Arterial Disease | 189 | Jun 2011actual | — | 2012-12-11 |
| Renal Safety Evaluation After Dotarem®-Enhanced MRINCT00650845results2015-06-09Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.Non-randomized · Open-label · Diagnostic | Phase 4 | Completed | Drug: Dotarem®-enhanced MRI · Other: non-enhanced MRI | Renal Insufficiency | 135 | May 2011actual | — | 2015-06-09 |
| Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)NCT00980681results2016-05-26Percent of Non Assessable Renal Artery SegmentsNon-randomized · Open-label · Diagnostic | Phase 3 | Terminatedsponsor's stated reason: Lack of recruitment. | Drug: Dotarem · Other: Time of Flight | Renal Disease | 13 | Dec 2010actual | — | 2016-05-26 |
| Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)NCT01010932results2015-08-25Technical Failure RateOpen-label · Diagnostic | Phase 3 | Completed | Drug: Dotarem · Other: TOF MRA | Cerebral Arterial Diseases | 222 | Dec 2010actual | — | 2016-06-16 |
| Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)NCT01012674results2015-08-25Technical Failure RateOpen-label · Diagnostic | Phase 3 | Completed | Drug: Dotarem · Other: TOF MRA | Cerebral Arterial Diseases | 211 | Dec 2010actual | — | 2016-06-16 |
| DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial DiseasesNCT00955617results2012-11-02Overall Image Quality of MRA ImagesRandomized · Quadruple-masked · Diagnostic | Phase 4 | Completed | Other: Contrast-enhanced MRA - Imaging examination | Peripheral Arterial Disease | 20 | Jun 2010actual | — | 2012-11-02 |
| Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)NCT00845702results2012-09-19Percent of Non Assessable Renal Artery SegmentsNon-randomized · Open-label · Diagnostic | Phase 3 | Terminatedsponsor's stated reason: lack of recruitment. | Drug: Gadoterate meglumine (Dotarem) · Other: Time of Flight Magnetic Resonance Angiography | Renal Artery Stenosis | 33 | Feb 2010actual | — | 2016-05-20 |
| Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed TomographyNCT00793182results2017-09-29Percentage of Patients With Contrast-induced Nephropathy (CIN)Randomized · Triple-masked · Other | Phase 4 | Terminatedsponsor's stated reason: Slow enrollment | Drug: Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL | Renal Impairment | 6 | Jun 2009actual | — | 2019-03-06 |
| A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric IndicationsNCT00347022results2013-04-09Creatinine ClearanceRandomized · Triple-masked · Diagnostic | Phase 4 | Completed | Drug: Xenetix, Visipaque | Diagnostic Imaging | 145 | Apr 2009actual | — | 2013-04-09 |
| A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal AngiographyNCT00382317Randomized · Double-masked · Diagnostic | Phase 4 | Completed | Drug: Iobitridol | Diagnostic Imaging | — | Feb 2008actual | — | 2008-11-26 |
| A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) AngiographyNCT00447889Non-randomized · Open-label | Phase 4 | Completed | Drug: gadoteric acid | Arterial Occlusive Disease | — | Nov 2007actual | — | 2008-11-26 |
| Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric PatientsNCT01092754Assess efficacy by analyzing the clinical diagnosis, degree of confidence in diagnosis and level of conspicuity of lesions.Non-randomized · Open-label · Diagnostic | Phase 4 | Completed | Procedure: MRI, MRI · Drug: Gadoversetamide | Pathological Processes | 100 | Dec 2003actual | — | 2017-08-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19